Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
abacavir, abatacept, accident, accomplished, Actemra, adult, airway, ALT, ambulatory, Amgen, anin, antibody, Avanir, Beth, Bink, biomarker, Boerhinger, brecanavir, bronchial, brought, Bucknell, budgetary, Cantley, carbamazepine, category, cessation, chain, classifed, Columbia, compromise, Cornell, corrector, creatinine, denufosol, designee, die, digital, diminished, disability, displayed, dispoproxil, disruption, diversification, DMARD, drop, drugable, Eastern, Edmund, education, educational, elderly, electrocardiogram, electrocardiographic, English, enzymology, epithelial, erlotinib, Error, EULAR, exempt, exhange, facilitate, footage, France, frequency, Fridericia, FSP, fumerate, Garrison, gastrointestinal, gyrA, gyrB, harm, HARMED, highest, Holland, Idenix, imatinib, impossible, impractible, improper, inconclusive, Ingleheim, inhaled, input, Inspire, Iowa, IRB, irreversible, Israel, Italy, itching, Johanna, kinetic, labor, landscape, largest, lt, lymphoma, managerial, mandatory, markedly, Messina, mesylate, methodology, mitigate, MMA, modern, Modernization, modification, monoclonal, morbidity, morning, mortality, msec, myeloma, neopterin, neutropenia, nonsense, Northeastern, Orencia, Organizational, outsource, oversee, parC, parE, plasma, political, pollution, polymerase, Predix, predominated, Premature, Princeton, proceed, Prograf, Programme, propriety, PTC, Publishedin, QTcF, quantitation, Quinn, rash, raw, RBV, recommend, recurrent, redefine, reducedin, reevaluate, relaxation, remuneration, rentable, residual, responsiblity, retonavir, retrospective, risky, Rituxan, rituximab, salt, Sandoz, secret, shipping, shorten, Sidney, simulation, simultaneously, skin, Southwestern, Spain, subtype, supplier, surface, suspension, swollen, syndrome, tablet, tableting, Takeda, TaqMan, tenofovir, tetrasodium, TheraCLEC, Theravance, tocilizumab, TolerRx, tort, Transduction, transmembrane, ultrasensitive, unanticipated, uncovered, unexpected, unforeseen, unqualified, upper, valopicitabine, variant, Vassar, VaxGen, vendor, Vitae, vulnerable, water, widespread, workplace
Removed:
activate, activation, additive, addressing, adequately, affiliated, Africa, Ahab, alanine, alpha, aminotransferase, Anthony, antiretroviral, artery, asthma, auditing, augmented, Berkeley, BMS, carbamezepine, cascade, CDC, Chair, characteristic, collaborated, collectively, complement, complementary, concert, conclusion, conflict, conformation, congestive, consolidation, consultant, context, contrast, convenient, CPA, created, Crohn, cycle, deciding, deleted, Dermatology, description, designate, detecting, determination, discretion, distort, District, druggable, dupont, earn, eliminate, enabled, enabling, encountered, entail, equally, essentially, establishment, excluded, executed, expectation, exploratory, expose, faculty, forgive, Fritz, GFP, GSK, guanine, helicase, HMR, impacted, indirectly, inhibiting, initiating, insight, internationally, ischemia, ix, lawsuit, ligand, lipid, MA, mechanism, mediated, merged, metabolite, middle, month, myocardial, native, NEAT, negotiate, nelfinavir, neurophilin, Neuroscience, newer, OA, offered, operational, optical, optional, overlapping, Oxfordshire, Pamela, participated, persist, pharmacological, phenomenon, positioned, postdoctoral, preferentially, progressive, promote, prove, Prozei, quantify, Radcliffe, regeneration, released, remained, removal, resignation, resistance, responded, restructured, satisfactory, Sato, selectively, Serono, serve, settlement, shortly, SOLO, sought, Stanford, stroke, studied, subunit, supplement, Taisho, throughput, tied, trend, triple, uncontrolled, underwent, undesirable, unit, unresponsive, unspecified, validate, variable, vi, Vicki, vii, viii, vying, West
Filing tables
Filing exhibits
VRTX similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
AMENDMENT TO NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
In the first quarter of 2006, the Board of Directors amended the Company's non-employee director compensation policy. Prior to the amendment, the Chair of the Audit Committee received a $15,000 annual retainer, and the Chair of the Management Development and Compensation Committee received a $10,000 annual retainer. Under the amended policy, the Chair of the Audit Committee will receive a $20,000 annual retainer, and the Chair of the Management Development and Compensation Committee will receive a $14,000 annual retainer.